Skip to main content

Marina Tarrés Mercader

Institutions of which they are part

Research technician
Gene Therapy at Nervous System
Vall Hebron Institut de Recerca

Marina Tarrés Mercader

Institutions of which they are part

Research technician
Gene Therapy at Nervous System
Vall Hebron Institut de Recerca

Projects

ESTUDIO Y DESARROLLO DE LA PRIMERA PLATAFORMA TECNOLÓGICA DE ENSAYOS PARA VIRUS ADENOASOCIADOS EN TERÁPIA GÉNICA

IP: Miguel Chillon Rodriguez
Collaborators: Susana Miravet Delgado, Laia Rubio Ortega, Marina Tarrés Mercader, ESTUDIO Y DESARROLLO DE LA PRIMERA PLATAFORMA TECNOLÓGICA DE ENSAYOS PARA VIRUS ADENOASOCIADOS EN TERÁPIA GÉNICA
Funding agency: Instituto de Salud Carlos III
Funding: 296571
Reference: PMPTA22/00048
Duration: 01/01/2023 - 30/06/2025

Related news

The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB) with the participation of VHIR.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

This gene therapy protects mice against cognitive deficits associated with aging, improves motor function, and delays the onset of diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

Related professionals

Laura Murillo Sanjuán

Laura Murillo Sanjuán

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
Júlia Comulada Ferrer

Júlia Comulada Ferrer

Research technician
Clinical Neuroimmunology
Read more
Claudia Maria Herrera de Guise

Claudia Maria Herrera de Guise

Postdoctoral researcher
Physiology and Pathophysiology of the Digestive Tract
Read more
CINTHYA FLORES LAMAS

CINTHYA FLORES LAMAS

Clinical Trials Management Unit
Clinical Research Development Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.